• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA accepts BMS’s application for non-small cell lung cancer treatment pharmaceutical-technology
    June 28, 2018
    The US Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb Company’s (BMY) supplemental biologics licence application (sBLA) for Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) to treat first-line advanced non-small cell lung cancer

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service